|
Progress in the Management of Pregnancy with Paroxysmal Nocturnal Hemoglobinuria: A Review |
Jan 2024 |
Journal of Women's Health |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Is there a path forward for immunotherapy in patients with myelodysplastic syndromes? |
Jan 2024 |
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
|
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial |
Jan 2024 |
Lancet |
Myelodysplastic Syndromes (MDS) |
|
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study |
Jan 2024 |
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
|
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial |
Jan 2024 |
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
|
Haploidentical Transplant with Post-Transplant Cyclophosphamide for Acute Myeloid Leukaemia and Myelodysplastic Syndromes Patients: The Role of Previous Lines of Therapy |
Jan 2024 |
Mediterranean Journal of Hematology and Infectious Diseases |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Paroxysmal Nocturnal Hemoglobinuria |
Jan 2024 |
StatPearls |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Morphologic Characteristics of Myelodysplastic Syndromes |
Dec 2023 |
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
|
Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes |
Dec 2023 |
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
|
Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists |
Dec 2023 |
Clinics in Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
